Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Dec;39(12):2381-6.
doi: 10.1124/dmd.111.041806. Epub 2011 Sep 22.

Inhibition of human liver aldehyde oxidase: implications for potential drug-drug interactions

Affiliations

Inhibition of human liver aldehyde oxidase: implications for potential drug-drug interactions

John T Barr et al. Drug Metab Dispos. 2011 Dec.

Abstract

During the course of our research efforts to understand the kinetics of human aldehyde oxidase as a xenobiotic-clearing enzyme, we investigated the effect of eight different inhibitors on the oxidation of the probe substrate phthalazine. Saturation kinetic parameters for phthalazine oxidation in human liver cytosol were found to be the following: K(m) = 8.0 ± 0.4 μM and V(max) = 4.3 ± 0.1 nmol · min(-1) · mg protein(-1). Inhibitory potency of the inhibitors tested ranged from 0.1 to 5 μM. Of the eight different inhibitor compounds tested, seven were observed to inhibit through a mixed mode and one through a strictly competitive mode. A ratio of the K(ii) and K(is) values was used to assess the relative competitiveness of each inhibitor. For the mixed inhibitors, the mode of inhibition varied from mostly uncompetitive to predominantly competitive (K(ii)/K(is) values ranging from 0.1 to 15). The implications for potential drug-drug interactions and inhibition mechanism are discussed. We found two inhibitors, clozapine and chlorpromazine, that have a moderate predicted risk of drug-drug interactions based on the K(i) value relative to the inhibitor concentration in human plasma, having a calculated [I]/K(i) value of 0.4 and 0.8, respectively.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Structures of human liver aldehyde oxidase inhibitors.
Fig. 2.
Fig. 2.
Oxidation reaction of phthalazine to 1-phthalazinone. The structure of the internal standard (IS) used for mass spectrometry assay is provided on the right.
Fig. 3.
Fig. 3.
Saturation kinetics plot for oxidation of phthalazine. Each point represents an average ± S.E. for a minimum of eight different experiments.
Fig. 4.
Fig. 4.
Lineweaver-Burk plots and slope/intercept replots of phthalazine oxidation inhibition by eight different inhibitors: DCPIP (A), estradiol (B), menadione (C), ethinyl estradiol (D), domperidone (E), chlorpromazine (F), clozapine (G), and 6-chloroquinazolinone (6-CQ) (H). Each point reflects the average of triplicate determinations.

Similar articles

Cited by

References

    1. Alfaro JF, Joswig-Jones CA, Ouyang W, Nichols J, Crouch GJ, Jones JP. (2009) Purification and mechanism of human aldehyde oxidase expressed in Escherichia coli. Drug Metab Dispos 37:2393–2398 - PMC - PubMed
    1. Bachmann KA. (2006) Inhibition constants, inhibitor concentrations and the prediction of inhibitory drug drug interactions: pitfalls, progress and promise. Curr Drug Metab 7:1–14 - PubMed
    1. Beedham C, Miceli JJ, Obach RS. (2003) Ziprasidone metabolism, aldehyde oxidase, and clinical implications. J Clin Psychopharmacol 23:229–232 - PubMed
    1. Bibi Z. (2008) Role of cytochrome P450 in drug interactions. Nutr Metab (Lond) 5:27. - PMC - PubMed
    1. Blanchard N, Richert L, Coassolo P, Lavé T. (2004) Qualitative and quantitative assessment of drug-drug interaction potential in man, based on Ki, IC50 and inhibitor concentration. Curr Drug Metab 5:147–156 - PubMed

Publication types

MeSH terms

Substances